COVID-19 and the role of chronic inflammation in patients with obesity
Top Cited Papers
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Obesity
- Vol. 44 (8), 1790-1792
- https://doi.org/10.1038/s41366-020-0597-4
Abstract
Coronavirus disease 2019 (COVID-19) and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a particular risk to people living with preexisting conditions that impair immune response or amplify pro-inflammatory response. Low-grade chronic systemic inflammation, common in people with obesity, is associated with the development of atherosclerosis, type 2 diabetes, and hypertension, well known comorbidities that adversely affect the outcomes of patients with COVID-19. Risk stratification based on the Edmonton Obesity Staging System (EOSS), which classifies obesity based on the presence of medical, mental, and/or functional complications rather than on body mass index (BMI), has been shown to be a better predictor of all-cause mortality and it may well be that EOSS stages may better describe the risk of hyperinflammation in patients with COVID-19 infection. Analyzing a group of metabolic ill patients with obesity (EOSS 2 and 3), we found an increased interleukin-6 and linear regression analysis showed a positive correlation with C-reactive protein (CRP) (p = 0.014) and waist-to-hip-ratio (WHR) (p = 0.031). Physicians should be aware of these findings in patients with COVID-19 infection. Early identification of possible hyperinflammation could be fundamental and should guide decision making regarding hospitalization, early respiratory support, and therapy with immunosuppression to improve mortality.Keywords
This publication has 20 references indexed in Scilit:
- Comorbidities and multi-organ injuries in the treatment of COVID-19The Lancet, 2020
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- Sex difference and smoking predisposition in patients with COVID-19The Lancet Respiratory Medicine, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortalityJournal of Leukocyte Biology, 2018
- Serum level of interleukin-6 (IL-6) and N-terminal propeptide of procollagen type I (PINP) in patients with liver diseasesScandinavian Journal of Clinical and Laboratory Investigation, 2017
- Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injuryRespiratory Research, 2017
- Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohortsThe Lancet Respiratory Medicine, 2016
- Severe acute respiratory infections in the postpandemic era of H1N1Current Opinion in Critical Care, 2012
- Inflammation and metabolic disordersNature, 2006